PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Pain (Nabumetone - Pain & inflammation - musculoskeletal)

Records returned : 23 (on 03 Jul 2024 at 08:45:03). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
10.01.01
Nabumetone
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
10.01.01
Celecoxib
Pain & inflammation - musculoskeletal
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Preferred COX II inhibitor for licensed indications
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Preferred
10.01.01
Naproxen
Pain & inflammation - musculoskeletal
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Preferred
10.01.01
10.03.02
Diclofenac sodium
Pain & inflammation - musculoskeletal
Green
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.01
10.03.02
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Restricted to use when oral NSAIDs are not an option.
10.01.01
10.03.02
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Ibuprofen or naproxen are the preferred NSAIDS. Diclofenac for use if 1st-line options are ineffective / not tolerated. Restriced at Trusts to Rheumatology only.
10.01.01
Naproxen
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Effervescent tablets
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Effervescent tablets and oral suspension are much more expensive and should be reserved for patients in whom ibuprofen suspension is not suitable. Reserve oral suspension for patients with sodium restriction or for children.
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Reserved for patients with swallowing difficulties
10.01.01
10.01.04
Etoricoxib
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
2nd line COXX II except for gouty arthritis where etoricoxib is the preferred COX II
10.01.01
Meloxicam
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Not a preferred NSAID, limited place in therapy. ASPH - rheumatology only.
07.01.01
10.01.01
Indometacin
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Capsules
  • Capsules (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Only for use in gout. ASPH restricted to rheumatology only.
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Restricted for patients where an oral NSAID is not suitable
10.01.01
10.03.02
Diclofenac sodium
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Modified release capsules
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
Ibuprofen or naproxen are the preferred NSAIDS. Standard release diclofenac may be considered if 1st-line NSAIDs are ineffective / not tolerated.
01.03.05
10.01.01
Naproxen with esomeprazole
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
10.01.01
Naproxen
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
More expensive that standard tablets and offer no additional gastro-protection.
10.01.01
Diclofenac sodium with misoprostol
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Capsules
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
10.01.01
Etodolac
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
10.01.01
10.03.02
Ketoprofen
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
10.01.01
Mefenamic acid
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
See separate entry for use in menorrhagia and dysmenorrhoea.
10.01.01
Aceclofenac
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.01
Diclofenac potassium
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More